Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
Oncology drugs are often approved for multiple indications, for which their clinical benefit varies. Aligning a single price to this differing value remains a challenge. This study examines the clinical and economic value, price, and reimbursement of multi-indication cancer drugs across seven countr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 July 2022
|
| In: |
Applied health economics and health policy
Year: 2022, Volume: 20, Issue: 5, Pages: 757-768 |
| ISSN: | 1179-1896 |
| DOI: | 10.1007/s40258-022-00737-w |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40258-022-00737-w Verlag, kostenfrei, Volltext: https://link.springer.com/content/pdf/10.1007/s40258-022-00737-w.pdf?pdf=button 
|
| Author Notes: | Daniel Tobias Michaeli, Mackenzie Mills, Panos Kanavos |
| Summary: | Oncology drugs are often approved for multiple indications, for which their clinical benefit varies. Aligning a single price to this differing value remains a challenge. This study examines the clinical and economic value, price, and reimbursement of multi-indication cancer drugs across seven countries, representing different approaches to value assessment, pricing, and coverage decisions: the USA, Germany, France, England, Canada, Australia, and Scotland. |
|---|---|
| Item Description: | Gesehen am 26.09.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1179-1896 |
| DOI: | 10.1007/s40258-022-00737-w |